Advertisement
Home Blog Page 3477
More frequent monitoring may be required when patients are taking both acenocoumarol and levofloxacin due to the possibility of an adverse interaction

Interaction Described Between Acenocoumarol, Levofloxacin

0
Probable interaction described in five patients, all of whom had atrial fibrillation
Neoadjuvant chemotherapy is less likely to benefit black women with breast cancer than those in other racial and ethnic groups

Early Chemo Less Likely to Help Black Breast Cancer Patients

0
More research needed to explain why outcomes differ among black, Hispanic, and Asian women
Patients with early-stage Alzheimer's disease who consume two to three alcoholic drinks a day may have a reduced risk of mortality compared to those who consume one or fewer drinks a day

Moderate Drinking May Benefit Early-Stage Alzheimer’s Patients

0
Two, three alcoholic drinks daily linked to reduced risk of death over three-year study period
The U.S. abortion rate has declined by more than one-third over the past two decades to a record low

CDC: U.S. Abortion Rate Hits Record Low

0
In 2010, for every 100 pregnancies, 65 ended in birth, 18 in abortion, and 17 in fetal loss
For patients with major depressive disorder

CYP2C19 Polymorphisms Impacts Citalopram Metabolism

0
CYP2C19*2 polymorphism seems to contribute to interindividual variability in CIT metabolism
The prevalence of hepatitis E virus is low in HIV-infected women and men

Hepatitis E Virus Rare Among HIV-Infected Population

0
Prevalence of HEV viremia three in 2,919 plasma samples from HIV-infected adults
For patients with knee osteoarthritis

Medial, Not Lateral, Femorotibial Cartilage Change Predictive of OA

0
Loss of medial femorotibial cartilage thickness linked to radiographic and pain progression
Alecensa (alectinib) has been approved by the U.S. Food and Drug administration to treat anaplastic lymphoma kinase-positive non-small-cell lung cancer

FDA Approves Alecensa for ALK-Positive NSCLC

0
Drug is designed to block the effects of the ALK protein
Vistogard (uridine triacetate) has been approved by the U.S. Food and Drug Administration to treat an overdose of the chemotherapy drugs fluorouracil and capecitabine

FDA Approves Vistogard to Treat Chemotherapy Overdose

0
For overdose of the chemo drugs fluorouracil and capecitabine
People with asthma may be more than twice as likely to develop chronic migraines as those without asthma

Asthma Tied to Increased Risk of Chronic Migraines

0
Researchers suggest asthma is stronger predictor of chronic migraines than depression